ISA Pharmaceuticals to present at the Virtual European Biotech Investor Day 2020

23 Jun 2020

Our CEO Gerben Moolhuizen will present on Thursday, June 25 at the Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.

Date: Thursday, June 25, 2020Time: 3:40pm CET / 9:40am EDT.Access to webcast: https://www.webcaster4.com/Webcast/Page/2408/35366

You may access the stream 15 minutes in advance and a replay of the webcast will be available for 60 days.

Read more »

Access to live broadcast ISA presentation at Virtual European Biotech Investor Day on June 25, 2020

22 Jun 2020

Date: Thursday, June 25, 2020

Time Europe: 3:40pm CET = Time US 9:40am EDT

Webcast: https://www.webcaster4.com/Webcast/Page/2408/35366

About ISA Pharmaceuticals

ISA Pharmaceuticals is an immunotherapy company developing treatments for various cancers and infectious diseases. ISA Pharmaceuticals has best-in-class technology to stimulate and activate the human immune system, specifically T cells, to fight diseased or infected cells. ISA Pharmaceuticals has a collaboration with Regeneron for its lead asset, ISA101b, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer. ISA101b is currently in a Phase 2 clinical trial for first- and second-line HPV16-induced head-and-neck cancer, in combination with Libtayo, a PD-1 antibody.

Read more »